Drawing for ATTMULTI

USPTO serial 88038659

ATTMULTI

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
LAVACHE, LINDA M
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ATTMULTI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Claudia A. Smith

Claudia A. Smith WHITE & CASE LLP1221 AVENUE OF THE AMERICASTRADEMARK DEPARTMENTNEW YORK, NY 10020

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy; pharmaceutical preparations and substances for the prevention and treatment of Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, dyskinesia, poor or absent motor functions, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP); pharmaceutical preparations and substances for the prevention and treatment of restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and chemical dependency; diagnostic agents, reagents, preparations and substances for medical purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Mar 14, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 14, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 13, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 12, 2021EX5GSOU EXTENSION 5 GRANTED—
Jul 8, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 29, 2021EXT5SOU EXTENSION 5 FILED—
Jun 29, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 22, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 20, 2021EX4GSOU EXTENSION 4 GRANTED—
Jan 20, 2021EXT4SOU EXTENSION 4 FILED—
Jan 20, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 25, 2020DOCKASSIGNED TO EXAMINER—
Jul 15, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 13, 2020EX3GSOU EXTENSION 3 GRANTED—
Jul 13, 2020EXT3SOU EXTENSION 3 FILED—
Jul 13, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 23, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 21, 2020EX2GSOU EXTENSION 2 GRANTED—
Jan 21, 2020EXT2SOU EXTENSION 2 FILED—
Jan 21, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 17, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 15, 2019EX1GSOU EXTENSION 1 GRANTED—
Jul 15, 2019EXT1SOU EXTENSION 1 FILED—
Jul 15, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 5, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 11, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 11, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 21, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 30, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 26, 2018DOCKASSIGNED TO EXAMINER—
Jul 19, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 19, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance